

# Critical Care Nursing

Monitoring and Treatment for  
Advanced Nursing Practice

EDITED BY

**Kathy J. Booker**



10045615

ห้องสมุด วพบ. สุรินทร์

**WILEY** Blackwell

# Contents

Contributors, xv

Critical Care Nursing: Monitoring and Treatment for Advanced Nursing Practice, xvii

*Kathy J. Booker*

## **1** Philosophy and treatment in US critical care units, 1

*Kathy J. Booker*

US critical care units, 1

Organization of critical care delivery, 1

Monitoring and surveillance in critical care, 2

Surveillance, 2

Nursing certification and competency in critical care units, 3

US national critical care organizations, 4

American Association of Critical Care Nurses, 4

Society of Critical Care Medicine, 5

Acute care advanced practice nursing, 5

Clinical nurse specialists, 6

Acute care nurse practitioners, 6

Critical care and ACNP outcomes research, 7

Evolution of families in the critical care unit, 8

Progression and development of rapid response teams, 9

## **2** Vital measurements and shock syndromes in critically ill adults, 13

*Kathy J. Booker and Laura Kierol Andrews*

Monitoring basic vital signs, 13

Temperature monitoring, 14

Hypothermia, 14

Complications of cooling, 15

Hyperthermia, 17

Heatstroke management, 17

Malignant hyperthermia, 17

Heart rate monitoring, 18

Blood pressure monitoring, 19

Oscillometric blood pressure measurement, 20

Aneroid measurement, 20

Arterial pressure measurement, 20

Respiratory monitoring, 21

Capnography, 21

Shock conditions in critically ill adults, 22

Cardiogenic shock, 23

Anaphylactic shock, 24

Hypovolemic shock, 24

Sepsis syndromes, 26

SIRS, sepsis, and septic shock, 26

- Monitoring and treatment priorities in sepsis syndromes, 28
- Sepsis diagnosis, 28
- Body temperature, 29
- Cultures, 29
- Intravascular catheters, 29
- Other infectious complications in critically ill adults, 29
- Pulmonary infections, 29
- Urinary tract infections, 30
- Monitoring during transport, 30
- 3** Monitoring for respiratory dysfunction, 35
  - Alexander P. Johnson and Jennifer Abraham*
  - Acid-base disturbances & anion gap, 35
    - Metabolic acidosis, 35
    - Metabolic alkalosis, 37
    - Respiratory acidosis, 37
    - Respiratory alkalosis, 38
    - Mixed acid–base disorders, 38
  - Oxygenation, 38
    - Estimation of the PaO<sub>2</sub>, 38
    - A–a Gradient, 39
    - PaO<sub>2</sub>/FiO<sub>2</sub> (P/F) ratio, 39
    - Acute respiratory failure, 40
  - Capnography, 40
    - Monitoring ventilation with PetCO<sub>2</sub>, 40
    - Monitoring blood flow, 41
  - Modes of mechanical ventilation, 41
    - Continuous positive airway pressure (CPAP) with pressure support, 41
    - Synchronized intermittent mandatory ventilation (SIMV), 42
    - Assist/control ventilation (AC), 42
    - Pressure control ventilation, 42
    - Airway pressure release ventilation (APRV), 42
    - Pressure-regulated volume control (PRVC), 42
    - Inverse ratio ventilation, 43
    - Oscillatory ventilation, 43
    - Overview of protective lung ventilation in ARDS, 43
    - ARDSNet protocol goals, 43
  - Monitoring for complications during mechanical ventilation, 43
    - High peak airway pressures on mechanical ventilation, 43
      - Response to bagging—monitoring and treatment, 44
    - Auto-PEEP effect, 44
  - Weaning from mechanical ventilation, 44
    - Postextubation stridor: Monitoring and treatment, 46
    - Noninvasive positive pressure ventilation, 47
    - Tension pneumothorax, 47
      - Emergent treatment—needle thoracostomy, 47
    - Chest radiograph interpretation, 48
  - Sleep-disordered breathing in the critical care unit, 48
    - Obstructive sleep apnea, 50
    - Central sleep apnea, 50
    - Obesity hypoventilation syndrome, 51

- CPAP and BiPAP therapy, 51
- Approach to cardiogenic dyspnea in acute heart failure, 52
- 4** Electrocardiographic monitoring for cardiovascular dysfunction, 57
  - Catherine Winkler*
  - Physiologic guidelines, 57
  - Goals of monitoring, 58
    - Post cardiopulmonary resuscitation, 59
    - Evidence-based treatment guidelines, 60
  - Acute coronary syndromes, 60
    - Evidence-based treatment guidelines, 62
  - Cardiac arrhythmias, 64
    - Evidence-based treatment guidelines, 65
  - Acute heart failure, 67
  - Electrolyte abnormalities, 67
    - Monitoring elements, 68
    - Evidence-based treatment guidelines, 68
  - Critical illnesses, 68
    - Evidence-based treatment guidelines, 68
  - Drug overdose, 69
    - Evidence-based guidelines, 69
  - Unnecessary arrhythmia monitoring and underutilization of ischemia and QT-interval monitoring, 69
- 5** Hemodynamic monitoring in critical care, 73
  - Kathy J. Booker*
  - Hemodynamic monitoring overview, 73
  - Hemodynamic monitoring systems, 75
    - Pulmonary artery catheter monitoring, 75
    - Central venous pressure monitoring and management, 76
      - Central venous pressure trending limitations, 77
    - Arterial line monitoring and management, 78
  - Hemodynamic monitoring guidelines and outcomes, 78
  - Functional indicators of hemodynamic monitoring, 79
    - Perioperative optimization, 79
  - Transesophageal monitoring, 79
  - Volume responsiveness, 80
  - Pulse contour analysis, 81
    - FloTrac/Vigileo®, 82
    - Transpulmonary dilution techniques, 82
    - Passive leg raising, 83
    - SVV protocols for management, 84
- 6** Monitoring for neurologic dysfunction, 87
  - Janice L. Hinkle and Carey Heck*
  - Physiological guidelines, 87
    - Increased intracranial pressure, 87
    - Decreased cerebral blood flow, 88
    - Cerebral response to increased intracranial pressure, 88
  - Rapid assessment of neurologic dysfunction in intensive care unit patients, 89
    - Evidence-based treatment guidelines, 90

- Intracranial pressure monitoring, 93
  - Evidence-based treatment guidelines, 93
- Measuring brain temperature, 94
  - Evidence-based treatment guidelines, 95
- Brain tissue O<sub>2</sub> monitoring, 95
  - Monitoring elements, 95
  - Evidence-based treatment guidelines, 95
- Microdialysis, 95
  - Monitoring elements, 95
  - Evidence-based treatment guidelines, 95
- Electrophysiological monitoring, 96
  - Monitoring elements, 96
  - Evidence-based treatment guidelines, 96
- The BiSpectral index monitoring, 96
  - Monitoring elements, 96
  - Evidence-based treatment guidelines, 96
- Transcranial Doppler ultrasonography, 97
  - Monitoring elements, 97
  - Evidence-based treatment guidelines, 97
- Shunts, 98
  - Monitoring elements, 98
  - Evidence-based treatment guidelines, 98
- Neuromuscular transmission, 98
  - Monitoring elements, 98
  - Evidence-based treatment guidelines, 98
- Management of cervical stabilization devices, 98
  - Monitoring elements, 98
  - Evidence-based treatment guidelines, 99
- Induced coma and sedation protocols, 100
  - Monitoring elements, 100
  - Evidence-based treatment guidelines, 100
- Research-based neurologic protocols, 100
- 7** Monitoring for renal dysfunction, 104
  - Dawn Cooper*
  - Acute kidney injury, 104
  - Physiological guidelines, 105
    - Prerenal injury, 105
    - Intrarenal injury, 106
      - Acute tubular necrosis, 107
      - Acute interstitial nephritis, 107
    - Post renal injury, 108
      - Monitoring elements, 108
      - History and physical assessment, 108
      - Laboratory analysis and data trending, 109
  - Diagnostic imaging, 111
  - Renal biopsy, 111
  - Evidenced-based treatment guidelines, 112
  - Prevention, 112
  - Hemodynamic monitoring, 112
    - Volume expansion, 112
    - Management of electrolyte and acid–base imbalance, 112

- Pharmacologic interventions, 113
- Prevention of radiocontrast nephropathy, 114
- Nutrition, 114
- Renal replacement therapy, 114
  - Intermittant hemodialysis, 114
  - Continuous renal replacement therapies, 114
  - Peritoneal dialysis, 115
- 8** Monitoring for blood glucose dysfunction in the intensive care unit, 119
  - Laura Kierol Andrews*
  - Diabetes management in the ICU, 119
    - Effects of hyperglycemia, 119
    - Hyperglycemia management recommendations, 120
      - Glucose monitoring, 120
      - Carbohydrate administration, 120
      - Insulin therapy, 121
      - Hypoglycemia management, 121
- 9** Monitoring for hepatic and GI dysfunction, 126
  - Eleanor R. Fitzpatrick*
  - Physiologic guidelines, 126
    - Gastrointestinal dysfunction, 126
    - Gastrointestinal bleeding, 128
  - Monitoring elements: Nasogastric decompression, 128
    - Evidence-based treatment guidelines, 129
    - Gastric pH, 129
    - Evidence-based treatment guidelines, 130
  - Monitoring elements: Laboratory tests for GI bleeding, 130
    - Evidence-based treatment guidelines, 130
  - Endoscopic procedures, 130
    - Evidence-based treatment guidelines, 131
    - Evidence-based treatment guidelines for stress ulcers, 132
  - Monitoring elements: Gastric tonometry and capnometry, 133
    - Evidence-based treatment guidelines, 134
  - Radiographic diagnostics, 134
    - Evidence-based treatment guidelines, 135
  - Ultrasonography, 135
    - Evidence-based treatment guidelines, 135
    - Intraabdominal pressure management, 135
    - Intraabdominal pressure measurement, 136
  - Treatment of abdominal compartment syndrome, 137
    - Diagnostics for liver function, 137
      - Evidence-based treatment guidelines, 138
    - Liver support devices, 138
      - Evidence-based treatment guidelines, 139
      - Balloon tamponade therapy, 139
      - Evidence-based treatment guidelines, 140
    - ICP monitoring in acute liver failure, 140
      - Evidence-based treatment guidelines, 140
      - Ascites management, 141
        - Evidence-based treatment guidelines: Paracentesis, 141
    - Nutritional assessment and treatment, 142

- Evidence-based treatment guidelines, 142
- Critical monitoring in acute pancreatitis, 142
  - Evidence-based treatment guidelines for acute pancreatitis, 143
  - Monitoring elements: pancreatitis, 143
  - Evidence-based treatment guidelines for acute pancreatitis, 143
- 10** Traumatic injuries: Special considerations, 146
  - Catherine Bond and Mary Beth Voights*
  - Primary, secondary, and tertiary surveys, 146
  - Fluid resuscitation, 151
    - Fluid choice, 151
    - End points of resuscitation, 152
  - Intracompartmental monitoring, 152
    - Complications, 153
    - Thromboembolic events, 153
    - Anticoagulation, 154
    - Pain management, 154
    - Early mobilization, 154
  - Thoracic injury management, 154
  - Abdominal trauma, 155
    - Abdominal compartment syndrome, 158
  - Musculoskeletal injuries and management, 159
    - Ongoing hemorrhage, 160
    - Pelvic fractures, 161
    - Crush syndrome management, 161
    - Pain management in orthopedic injury, 162
  - Burns, 162
    - Burn classification, 162
    - Fluid management in burn therapy, 164
- 11** Oncologic emergencies in critical care, 167
  - Lisa M. Barbarotta*
  - Evolution of oncology critical management, 167
    - Sepsis in the immunocompromised host, 167
      - Physiologic guidelines, 167
    - Assessment and monitoring in neutropenic patients, 168
    - Neutropenia management, 168
    - Evidence-based guidelines, 169
      - Research, 171
  - Stem cell transplant, 171
    - Infection, 172
      - Graft-versus-host disease, 172
      - Hepatic veno-occlusive disease, 173
      - Pulmonary complications, 174
    - Hematologic complications, 175
      - Hemorrhagic complications, 175
        - Thrombocytopenia, 175
        - Management, 176
      - Thrombotic microangiopathy, 177
        - Physiologic guidelines, 177
        - Management, 179

- Hyperviscosity syndromes, 179
  - Physiologic guidelines, 179
  - Management, 180
- Hyperleukocytosis and leukostasis, 180
  - Physiologic guidelines, 180
  - Management, 181
- Tumor lysis syndrome, 181
  - Physiologic guidelines, 181
  - Treatment, 183
- Management of electrolyte imbalances, 184
  - Hyperkalemia, 184
  - Hyperphosphatemia with secondary hypocalcemia, 184
  - Hyperuricemia, 185
- Acute kidney injury, 186
  - Evidence-based treatment guidelines, 186
- Structural emergencies, 186
  - Cardiac tamponade, 187
    - Physiologic guidelines, 187
    - Management, 189
  - Malignant airway obstruction, 189
    - Physiologic guidelines, 189
    - Management, 190
  - Carotid blowout syndrome, 192
    - Physiologic guidelines, 192
    - Management, 194
- 12** End-of-life concerns, 201
  - Kathy J. Booker*
  - Introduction, 201
  - Assessment and communication issues, 201
  - Family presence, 202
  - Advanced directives, 202
    - Surrogate decision making, 202
  - Delivering bad news, 204
  - Palliative care in the ICU, 204
    - Symptom management, 206
  - Brain death, 206
- 13** Monitoring for overdoses, 210
  - Linda M. Dalessio*
  - Introduction, 210
    - General management of drug overdoses, 210
    - Drug screening, 210
    - New and emerging therapies, 211
  - Indexing of drug and toxins seen in overdoses, 212
    - Acetaminophen, 213
      - Drug overview, 213
      - Symptoms of overdose, 213
      - Diagnostic testing and monitoring, 213
      - Antidotes/binding agents, 213
    - Salicylates and nonsteroidal anti-inflammatory drugs, 214

- Drug overview, 214
- Symptoms of overdose, 214
- Monitoring, 214
- Antidotes/binding agents/treatment, 215
- Methemoglobin, 215
  - Drug overview, 215
  - Symptoms of overdose, 215
  - Diagnostic testing and monitoring, 216
  - Antidotes/binding agents/treatment, 216
- Iron, 217
  - Drug overview, 217
  - Symptoms of overdose, 217
  - Diagnostic testing and monitoring, 217
  - Antidotes/binding agents/treatment, 217
- Drugs of abuse, 218
  - Overview, 218
  - Symptoms of overdose, 218
  - Diagnostic testing, 218
- Benzodiazepines, 218
  - Drug overview, 218
  - Symptoms of overdose, 218
  - Diagnostic testing and monitoring, 219
  - Antidotes/binding agents/treatments, 219
- Opioids, 219
  - Drug overview, 219
  - Symptoms of overdose, 219
  - Diagnostic testing and monitoring, 220
  - Antidotes/binding agents/treatment, 220
- Cocaine, 220
  - Drug overview, 221
  - Symptoms of overdose, 221
  - Diagnostic testing and monitoring, 221
  - Antidotes/binding agents/treatment, 222
- Amphetamines, 222
  - Drug overview, 222
  - Symptoms of overdose, 222
  - Diagnostic testing and monitoring, 222
  - Antidotes/binding agents/treatments, 223
- Phencyclidine, 223
  - Drug overview, 223
  - Symptoms of overdose, 223
  - Diagnostic testing and monitoring, 223
  - Antidotes/binding agents/treatments, 223
- Barbituates, 224
  - Drug overview, 224
  - Symptoms of overdose, 224
  - Diagnostic testing and monitoring, 224
  - Antidotes/binding agents/treatments, 224
- Hallucinogens, 224
  - Drug overview, 224
  - Symptoms of overdose, 225

- Monitoring and treatment, 225
- Club drugs/date rape drugs, 225
  - Drug overview, 225
  - Symptoms of overdose, 225
  - Diagnostic testing and monitoring, 226
  - Antidotes/binding agents/treatments, 226
- Ketamine, 226
  - Drug overview, 226
  - Symptoms of overdose, 226
  - Diagnostic testing and monitoring, 227
  - Antidotes/binding agents/treatments, 227
- Fake marijuana, 227
  - Drug overview, 227
  - Symptoms, 227
  - Diagnostic testing, 227
  - Antidote, 228
- Dextromethorphan, 228
  - Drug overview, 228
  - Symptoms of overdose, 228
  - Diagnostic testing and monitoring, 228
  - Antidotes, 229
- Bath salts, 229
  - Drug overview, 229
  - Symptoms of overdose/use, 229
  - Diagnostic testing and monitoring, 229
  - Antidotes/binding agents/treatments, 229
- Skeletal muscle relaxants, 230
  - Drug overview, 230
  - Symptoms of overdose, 230
  - Diagnostic testing and monitoring, 230
  - Antidotes/binding agents/treatments, 231
- Psychiatric drugs, 231
  - Drug overview, 231
- Selective serotonin reuptake inhibitors, 231
  - Drug overview, 231
  - Symptoms, 231
  - Diagnostic testing and monitoring, 234
  - Antidotes/binding agents/treatments, 234
- Monoamine oxidase inhibitors, 234
  - Drug overview, 234
  - Symptoms of overdose, 235
  - Diagnostic testing and monitoring, 235
  - Antidotes, 235
- Lithium, 236
  - Drug overview, 236
  - Symptom of overdose, 236
  - Diagnostic testing and monitoring, 236
  - Antidotes/binding agents/treatments, 236
- Neuroleptics, 237
  - Drug overview, 237
  - Symptoms of overdose, 237

- Diagnostic testing and monitoring, 237
- Antidotes/binding agents/treatments, 237
- Tricyclic antidepressants, 238
  - Drug overview, 238
  - Symptoms of overdose, 238
  - Diagnostic testing and monitoring, 238
  - Antidotes/binding agents/treatments, 238
- Carbon monoxide, 239
  - Drug overview, 239
  - Pharmacology, 239
  - Symptoms, 239
  - Diagnostic testing and monitoring, 239
  - Antidotes/binding agents/treatments, 240
- Hydrocarbons and toxic inhalants, 240
  - Drug overview, 240
  - Pharmacology, 240
  - Diagnostic testing and monitoring, 241
  - Signs and symptoms, 241
  - Antidotes/treatment, 241
- Cardiac medications, 241
  - Drug overview, 241
  - Antiarrhythmic agents, 246
- Toxic alcohols, 248
  - Drug overview, 248
- Anticholinergics/Cholinergics/Antihistamines (ACA), 251
  - Drug overview, 251
  - ACA symptoms of overdose, 252
  - ACA diagnostic testing and monitoring, 252
  - ACA antidotes/binding agents/treatment, 252
- Anticonvulsants, 252
  - Drug overview, 252
  - Anticonvulsants symptoms of overdose, 253
  - Anticonvulsants diagnostic testing and monitoring, 253
  - Anticonvulsants antidotes/binding agents, 253
- Common toxidromes and treatments for poisoning conditions, 253
  - Anticholinergic toxidrome, 255
  - Benzodiazepine toxidrome, 255
  - Cholinergic toxidrome, 256
  - Opioid toxidrome, 256
  - Sympathomimetic toxidromes, 256
  - Rhabdomyolysis syndromes, 257
  - Treatment of hyperkalemia, 257
  - Packidrome, 257
  - Alcohol withdrawal syndrome, 258
- Anion and non-anion gap acidosis and osmolar anion gap, 258
  - Non-anion gap acidosis, 259
  - Osmolar gap, 259
    - Osmolarity corrected for elevated ETOH level, 259
- Index, 264